Where can researchers source third-party tested BPC-157?

Midwest Peptide supplies research-grade BPC-157 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

BPC-157 Origin Research: Gastric Juice History | Midwest Peptide

BPC-157 Tendon and Ligament Research: Animal Model LiteraturePrev|BPC-157 in Research: A Comprehensive Body Protection Compound Literature ReviewNext

BPC-157 Origins: From Gastric Juice to Research Peptide

BPC-157 · Published April 9, 2026 · Updated May 18, 2026 · 9 min read

Quick Answer

BPC-157 originated as a fragment of a body protective compound identified in human gastric juice, characterized as a stable pentadecapeptide for preclinical research in the 1990s. Studies established its sequence, stability profile, and broad use across rodent tissue repair literature. For research use only, not for human consumption.

BPC-157 Origins: From Gastric Juice to Research Peptide

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

Gastric Juice and Protective Factors
Identification of BPC-157
Why a Pentadecapeptide?
Stability of BPC-157 in Research
BPC-157 Synthesis and Characterization
Research Programs Studying BPC-157
BPC-157 in the Broader Peptide Research Landscape
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

BPC-157 origin research provides the historical and biochemical foundation for understanding the peptide as a research tool. BPC-157 emerged from research on gastric juice and on the protective factors that contribute to gastric mucosal integrity beyond the better known mucus and bicarbonate barriers. As the historical and biochemical background component of the BPC-157 research cluster, this article reviews the published literature on the origin of BPC-157, its identification from gastric juice protective sequences, and the development of the synthetic pentadecapeptide as a research compound.

Frequently Asked Questions

What is BPC-157 in research contexts?

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a protective sequence found in human gastric juice. It is studied in preclinical rodent models for its effects on tissue repair, vascular signaling, and cytoprotection.

How was BPC-157 originally discovered?

BPC-157 was identified by researchers at the University of Zagreb as a 15-amino-acid fragment within a larger gastric protective protein found in human gastric juice. The discovery group led by Dr. Sven Sikiric remains the most prolific publishing group on BPC-157.

Why is BPC-157 considered a stable research peptide?

BPC-157 demonstrates unusual stability in gastric acid, resistance to enzymatic degradation, and a long shelf life as a research-grade peptide compared to many other small peptides used in preclinical research.

Is BPC-157 approved for human use?

No. BPC-157 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

Pentadecapeptide: A peptide chain composed of 15 amino acid residues linked by peptide bonds.
Cytoprotection: The biological process by which cells are protected from injury caused by chemical, ischemic, or oxidative insults.
Angiogenesis: The formation of new blood vessels from pre-existing vasculature, central to tissue repair.
VEGF: Vascular Endothelial Growth Factor, a signaling glycoprotein that stimulates new blood vessel formation.
Nitric Oxide (NO): A short-lived gaseous signaling molecule that triggers vasodilation and supports endothelial function.
Gastric Juice: The acidic fluid secreted by gastric glands containing HCl, pepsinogen, and protective peptide sequences.
University of Zagreb: The Croatian university where the original BPC-157 research program was established.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. BPC-157 is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of an authorized research protocol.

Gastric Juice and Protective Factors

The stomach is exposed to highly acidic conditions and to digestive enzymes that would damage most tissues, but the gastric mucosa remains intact under normal conditions. The protection of gastric tissue from this harsh environment involves multiple mechanisms, including a mucus barrier that physically separates the mucosa from the luminal contents, bicarbonate secretion that neutralizes acid at the mucosal surface, and various other protective factors.

Research into gastric protection identified additional protective factors beyond the better known mucus and bicarbonate components. These additional factors include various peptides and proteins that contribute to gastric mucosal integrity through mechanisms that are still being characterized in research. The recognition that gastric juice contains protective sequences with biological activity beyond the known protective mechanisms motivated research into identifying and characterizing these additional factors.

The research on gastric protective factors was driven in part by interest in understanding the molecular basis of gastric mucosal protection and in part by interest in identifying potential research tools for studying tissue repair and protection in other contexts. The success of the gastric juice research in identifying biologically active peptide fragments validated the broader approach of looking for protective factors in tissues with high resistance to damage.

Identification of BPC-157

BPC-157 was identified in the 1990s as a 15 amino acid sequence derived from a protective protein found in human gastric juice. The full protective protein from which BPC-157 was derived has not been completely characterized in the published literature, but the pentadecapeptide fragment was selected for further study based on its stability and its activity in early rodent injury models.

The naming convention for BPC-157 reflects the research history. "Body Protection Compound" indicates the original research interest in protective factors, and "157" is an identifier from the research program that distinguished this particular peptide from other candidates that were identified and characterized. The numerical designation has become the standard reference for the peptide in the broader research literature.

The identification of BPC-157 involved enzymatic processing of gastric juice samples to release peptide fragments, followed by characterization of the fragments using various analytical methods. The 15 amino acid sequence was identified through this process and synthesized for further research. The synthesized peptide has been the subject of extensive subsequent research as a stable research compound that can be reliably produced and characterized.

Why a Pentadecapeptide?

The 15 amino acid length of BPC-157 places it in the pentadecapeptide category, which is a relatively common length for peptide research compounds. The choice of this specific length was driven by the original identification of this fragment as a biologically active sequence within the larger gastric juice protective protein.

The pentadecapeptide length provides several practical advantages for research applications. The peptide is small enough to be efficiently synthesized using standard solid-phase peptide synthesis methods, which makes it accessible for research without requiring specialized synthesis approaches. The length is also large enough to encode complex biological activity through specific structural features and amino acid interactions.

The specific sequence of BPC-157 has been characterized in detail and has been shown to be functionally important. The order of amino acids contributes to the peptide's stability against enzymatic degradation and to its biological activity. Modifications to the sequence generally produce peptides with different research profiles, supporting the conclusion that the specific BPC-157 sequence is an important contributor to its research properties.

Stability of BPC-157 in Research

A defining feature of BPC-157 in preclinical research is its stability. The peptide is generally described in the published literature as being relatively resistant to degradation in gastric and other body fluid conditions, which has made it useful as a research tool for studies that require sustained activity rather than rapid clearance.

The stability of BPC-157 in research conditions has been characterized through various analytical methods that measure peptide concentrations over time in different solution conditions. The published findings support relative stability under conditions that would rapidly degrade many other research peptides. The mechanism of this stability is related to the specific sequence and structural features of the peptide, which provide resistance to the proteolytic enzymes that typically degrade short peptides.

The stability advantage is particularly important for research applications that involve oral delivery, since peptides delivered orally must survive the gastric and intestinal environment to reach systemic circulation. The relative resistance of BPC-157 to gastric degradation supports the use of oral delivery routes in research, including the BPC-157 Capsules formulation supplied by Midwest Peptide.

BPC-157 Synthesis and Characterization

Modern BPC-157 research uses synthetic peptide that is produced by solid-phase peptide synthesis methods rather than isolated from gastric juice. The synthetic approach provides several advantages over the original isolation approach, including consistent purity, reliable supply, and the ability to produce specific quantities for research applications.

The synthetic BPC-157 used in modern research is characterized by analytical methods including high-performance liquid chromatography (HPLC) for purity assessment, mass spectrometry for molecular identity confirmation, and amino acid analysis for sequence verification. These characterization methods provide the quality control data that researchers need to ensure that the peptide they are using matches the expected structure and purity specifications.

The Certificate of Analysis supplied with BPC-157 10mg provides the relevant identity and purity information for research applications. The COA documentation supports research grade handling decisions and provides the data needed for research protocols that require quality control documentation.

Research Programs Studying BPC-157

Multiple research groups have studied BPC-157 since its identification in the 1990s. The most active research has originated from groups in Croatia and other European countries, with additional contributions from research groups in other regions. The accumulated literature represents work by many independent research groups, providing convergent evidence on the biological effects of the peptide.

The international scope of BPC-157 research is one of the more notable features of the broader literature. The convergence of findings across geographically and methodologically distinct research groups supports the conclusion that the peptide has reproducible effects in research models rather than effects specific to particular research conditions or methodologies.

The continued growth of the BPC-157 research literature over the past several decades reflects the ongoing interest in the peptide as a research tool for studying tissue repair, gastrointestinal biology, and various other research questions. Each year brings new published studies that extend the research base and characterize new aspects of the peptide's biological activity.

BPC-157 in the Broader Peptide Research Landscape

BPC-157 is part of a broader category of synthetic research peptides that have been derived from biologically active sequences in larger proteins. Other examples include various neuropeptide fragments, growth factor fragments, and other peptides that retain biological activity when isolated from their parent proteins. The general approach of identifying active sequences within larger proteins has produced many useful research tools.

The BPC-157 example is particularly notable because of the specific origin in gastric juice and the focus on protective factors. Other peptide research tools have been derived from different protein sources and target different biological processes, providing a diverse landscape of research compounds for various research applications.

For more on how BPC-157 is studied alongside other peptides in multi-peptide research formulations, see our KLOW peptide blend research overview.

Open Research Questions

Several open research questions remain in the BPC-157 origin research literature. These include the precise identification and characterization of the larger protective protein from which BPC-157 is derived, the molecular mechanism by which the BPC-157 sequence resists enzymatic degradation, and how the original gastric juice protective function relates to the broader biological effects of the peptide in research models. Each of these is a legitimate research opportunity for investigators studying peptide research tool development.

Conclusion

BPC-157 origin research provides the historical and biochemical foundation for understanding the peptide as a research tool. The identification of BPC-157 from gastric juice protective sequences, the selection of the 15 amino acid pentadecapeptide form, the characterization of its stability advantages, and the development of synthetic production methods all combine to position BPC-157 as one of the more practical research tools available for tissue repair and gastrointestinal research. For investigators using BPC-157 10mg or BPC-157 Capsules as research tools, the origin literature provides essential context for understanding the molecule.

For more on the full BPC-157 research cluster, see the pillar overview article and the supporting articles on each major topic.

BPC-157 is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

BPC-157 Capsules, 99%+ purity, COA included
GHK-Cu 50mg, 99%+ purity, COA included
BPC-157 10mg, 99%+ purity, COA included
KLOW 90mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

BPC-157 Origins: From Gastric Juice to Research Peptide